Bharat Parenterals Quarterly Results for Trading Insights
In Sept 2025, Bharat Parenterals (BPLPHARMA) reported revenue ₹68 Cr and net profit ₹-9 Cr — revenue -10.5% YoY. Analyse BPLPHARMA promoter holding to track promoter, FII and institutional holdings.
BPLPHARMA Quarterly Results — Revenue, Profit & EPS Highlights
Bharat Parenterals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Bharat Parenterals share price chart.
- Revenue of ₹68 Cr in Sept 2025 (-35.8% vs Mar 2025, -10.5% vs Sept 2024)
- Net Profit of ₹-9 Cr in Sept 2025 (+0.0% vs Mar 2025, +50.0% vs Sept 2024)
- EBITDA of ₹4 Cr in Sept 2025 (+0.0% vs Mar 2025)
- Operating Margin of 1.0% in Sept 2025 (-1.0pp vs Mar 2025)
- Earnings Per Share of ₹-14.00 in Sept 2025 (+2.8% vs Mar 2025)
Bharat Parenterals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
BPLPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 68 | 106 | 117 | 76 | 71 | -35.8% | -10.5% |
| Net Profit (₹ Cr) | -9 | -9 | -1 | -18 | -3 | - | - |
| EBITDA (₹ Cr) | 4 | 4 | 15 | -4 | 4 | - | - |
| EPS (₹) | -14.00 | -14.40 | -1.00 | -27.00 | -0.62 | - | - |
| Operating Margin (%) | 1.0% | 2.0% | 12.0% | -11.0% | 1.0% | - | - |
BPLPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results
Bharat Parenterals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. View BPLPHARMA 52-week chart for the annual high/low range and current price position.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
BPLPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Bharat Parenterals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹440,829.81 Cr | 1868.9 | 15,018 | 2,710 | -5.6% | - | 18.0% | 165.4 |
|
Divis Laboratories
Mar 2026 |
₹249,819.21 Cr | 9410.5 | 2,986 | 751 | -5.0% | - | 25.2% | 332.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4970.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.8 |
|
Zydus Life Science
Mar 2026 |
₹116,823.77 Cr | 1161.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.8 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1386.1 | 6,612 | 543 | -9.3% | - | 8.2% | 201.8 |
All amounts in ₹ Crores